SCHEMBL852874

SCHEMBL852874

Sc1nc2cc(-c3ccccc3)ccc2o1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
SMN1; SMN2 Q16637 4/20 0.46
CASP3 P42574 2/20 0.46
SENP7 Q9BQF6 2/20 0.46
SENP6 Q9GZR1 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 2/20 0.46
POLB P06746 1/20 0.46
SENP8 Q96LD8 1/20 0.46
PGR P06401 1/20 0.45
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
FBP1 P09467 2/20 0.41
PIK3R1 P27986 1/20 0.41
PIK3CA P42336 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29594461 1.00 GAA (0.65) GAAL3MBTL1SMN1; SMN2CASP3SENP7
SCHEMBL10939942 0.98 GAA (0.63) GAAL3MBTL1SMN1; SMN2CASP3SENP7
SCHEMBL10667529 0.86 L3MBTL1 (0.47) GAAL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL29878683 0.86 L3MBTL1 (0.47) GAAL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL28874458 0.84 ALDH1A1 (0.56) GAAL3MBTL1SMN1; SMN2CASP3SENP7
SCHEMBL14160785 0.84 GAA (0.45) GAAL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL28874293 0.83 L3MBTL1 (0.54) GAAL3MBTL1SMN1; SMN2CASP3SENP7
SCHEMBL29878660 0.83 L3MBTL1 (0.54) GAAL3MBTL1SMN1; SMN2CASP3SENP7
SCHEMBL7905531 0.80 SMN1; SMN2 (0.70) GAAL3MBTL1SMN1; SMN2CASP3SENP7
SCHEMBL2244575 0.80 SMN1; SMN2 (0.70) GAAL3MBTL1SMN1; SMN2CASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3686203-A1 4-SULFUR SUBSTITUTED PODOPHYLLOTOXIN DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF Tang, Yajie (CN) 2020-07-29 EP claimed
CN-111454308-A Teniposide derivative and preparation method and application thereof 湖北工业大学 2020-07-28 CN claimed
US-20200216462-A1 4-Sulfur Substituted Podophyllotoxin Derivative and Preparation Method Therefor and Use Thereof Tang, YaJie (CN) 2020-07-09 US claimed
US-20200216449-A1 4-Sulfur Substituted Podophyllotoxin Derivative and Preparation Method Therefor and Use Thereof Tang, YaJie (CN) 2020-07-09 US claimed
US-20250155812-A1 PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE RESIN FILM, PHOTOSENSITIVE DRY FILM, AND PATTERN-FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-05-15 US disclosed
CN-119987132-A Photosensitive resin composition, photosensitive resin coating film, photosensitive dry film and pattern forming method 信越化学工业株式会社 2025-05-13 CN disclosed
EP-4397502-A1 ON-MACHINE DEVELOPMENT-TYPE LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD FOR MANUFACTURING PRINTING PLATE FUJIFILM Corporation (JP) 2024-07-10 EP disclosed
US-20240208200-A1 ON-PRESS DEVELOPMENT TYPE LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD OF PREPARING PRINTING PLATE FUJIFILM CORPORATION (JP) 2024-06-27 US disclosed
US-20240110071-A1 Ultraviolet-Curable Water-Based Ink, Dispersion, Ultraviolet-Curable Water-Based Composition, and Printed Matter MITSUBISHI CHEMICAL CORPORATION (JP) 2024-04-04 US disclosed
EP-4328246-A1 ULTRAVIOLET-CURABLE AQUEOUS INK, DISPERSION, ULTRAVIOLET-CURABLE AQUEOUS COMPOSITION, AND PRINTED MATTER Mitsubishi Chemical Corporation (JP) 2024-02-28 EP disclosed
US-11874602-B2 Lithographic printing plate precursor, method for preparing lithographic printing plate, and lithographic printing method FUJIFILM CORPORATION (JP) 2024-01-16 US disclosed
CN-115124485-B Sulfoxide-containing benzoxazole derivative, and preparation method and application thereof 中国医学科学院药物研究所 2023-12-15 CN disclosed
WO-2009055357-A1 DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-30 WO disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US disclosed
US-6288236-B1 PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR HYPERLIPEMIA OR ARTERIAL SCLEROSIS. FUJI PHOTO FILM CO., LTD. (JP) 2001-09-11 US disclosed
US-6174907-B1 THERAPY AND PROPHYLAXIS OF HYPERLIPEMIA OR ARTERIAL SCLEROSIS; AS ADDITIVE OF A SILVER HALIDE PHOTOSENSITIVE MATERIAL, LIQUID CRYSTAL MATERIAL FUJI PHOTO FILM CO., LTD. (JP) 2001-01-16 US disclosed
US-5998456-A ANTILIPEMIC AGENTS FUJI PHOTO FILM CO., LTD. (JP) 1999-12-07 US disclosed
EP-0849259-A1 BENZIMIDAZOLE COMPOUNDS FUJI PHOTO FILM CO., LTD. (JP) 1998-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT GAA 62/4885L3MBTL1 244/4885SMN1; SMN2 41/4885
US-20200216462-A1 4-Sulfur Substituted Podophyllotoxin Derivative and Preparation Method Therefor and Use Thereof WEE1, WEE2, DHFR GAA 4521/4885L3MBTL1 350/4885SMN1; SMN2 4767/4885
US-20200216449-A1 4-Sulfur Substituted Podophyllotoxin Derivative and Preparation Method Therefor and Use Thereof TPMT, WEE1, DHFR GAA 4636/4885L3MBTL1 343/4885SMN1; SMN2 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.